The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison

Every GLP-1 platform advertises a number, and almost none of them is the number you pay. The membership excludes the medication. The medication price is the starting dose. The labs are extra, the intake is extra, and the maintenance dose costs more than anything on the pricing page. This guide works out the true all-in monthly cost across every major model, honestly, including ours.

Methodology: all platform prices below are the published self-pay rates as of August 2026, taken from each company's own pricing pages or manufacturer price lists, with sources cited at the end of this guide. All-in means program fee plus medication plus labs. Branded and compounded offerings are priced in separate tables because they are different product classes. Prices change; where a platform's price moves, the comparison logic here does not.

The honest comparison table

Two things stand out. First, the cheapest-looking options are not cheap once the medication is real. Second, the most expensive options are not buying more medicine — they are buying structure: intake fees, lab bundles, and margin.

The platforms, one by one, at August 2026 prices

One trait unites every competitor below, across both product classes: they are weight-loss verticals. They compete on access to a molecule and the price of delivering it. None of them is built to look at the person around the weight — the thyroid quietly stalling the protocol, the fasting insulin rising years before glucose moves, the ApoB that stays dangerous after the scale improves, the hormonal transition driving the weight in the first place. Hold that in mind as you read the prices, because it is what the prices do and do not contain.

Manufacturer direct — NovoCare and LillyDirect. The true market floor for the drug itself, and dramatically cheaper than two years ago: Wegovy pens are $349 a month at every dose through NovoCare (with a $199 introductory price on the first two low-dose fills), Wegovy tablets $149 to $199, Zepbound single-dose vials $299 to $449 through LillyDirect (the $449 maintenance price requires refilling within 45 days), and Foundayo from $149 to $349 by dose. What you get for that money is the medication — full stop. No named clinician, no comprehensive labs, no thyroid or hormone workup, no titration judgment beyond the label, no one accountable for whether your biology is actually improving.

Hims. Now the sharpest bundled price in the weight vertical: branded Wegovy including clinical support at $299 a month, oral Wegovy at $249, Zepbound at $399, having moved new patients off compounded semaglutide in 2026. The number is real, and this page says so plainly. What the bundle does not contain is the rest of the system: no comprehensive quarterly biomarker panels, no endocrine axis, no ApoB or Lp(a), no hormone optimization — a weight program, priced as one.

Ro. The advertised $149 to $249 track is compounded semaglutide — a copy of the molecule, not the FDA-reviewed branded product with its manufacturing controls, dosing device, and trial evidence. Branded medication through Ro costs substantially more. For a patient comparing on price alone, the compounded discount is the product; the comparison to branded therapy is not apples to apples.

Noom Med. Fees stack: roughly $99 a month for the base membership (billed quarterly) plus about $199 a month for the medication program on new accounts — before the medication, which is extra (branded Zepbound vials from $349). All-in on branded therapy, the stack commonly exceeds $650 a month, with a coaching-first clinical layer.

Sesame. The Success program at $99 per 28 days includes consults, basic labs, and messaging, with branded medication extra through the manufacturer channel — roughly $448 all-in on Wegovy. A fair low-cost branded path; the clinical layer is a weight program, not a cardiometabolic one.

WeightWatchers Clinic. Program pricing from a $25/month introductory rate (three months, with a 12-month commitment) to $149 month-to-month, medication extra — roughly $423 to $498 all-in on branded therapy. The behavioral layer is the product; comprehensive labs and the endocrine axis are not part of it.

LifeMD. A program fee of $79 to $149 a month with two tracks: branded Wegovy through its Novo Nordisk partnership at $349, or compounded semaglutide at $150 to $350 when available — which places one platform on both sides of the product-class line, roughly $428 to $498 all-in on the branded track.

Calibrate. The structural outlier: $199 a month, branded-only, with a metabolic-reset curriculum — but it requires commercial insurance that covers the GLP-1, so the medication cost is a copay and cash-pay patients cannot join at all. For the insured patient it is a legitimate branded path; for everyone else it is not a path.

Found and Mochi Health. The volume players of the compounded class: Found at $99 platform plus $199 to $299 for compounded semaglutide or liraglutide; Mochi at $79 membership plus $99 to $199 for compounded semaglutide or tirzepatide. The lowest absolute prices in the market — for the copied product class, with the caveats the next section prices in.

Concierge and hormone clinics. $900 to $1,500+ a month once intake fees ($299+), lab packages ($450+), and medication margin are counted. Often genuinely high-touch — and structurally priced on everything except your outcome.

GoodLife Health. One flat $299 for the entire clinical layer, and the medication routed through whichever channel is cheapest for your dose — including the manufacturer channels above, or your own insurance benefit where your plan covers it. The membership never moves; the medication is never marked up; and the routing means the market's price war on the drug works for you, not against you.

Why compounded is separated in this analysis

Compounded semaglutide and tirzepatide are listed in their own table because they are a different product class, not a discount on the same one. A compounded GLP-1 is a pharmacy-made copy: it has not passed FDA review of its manufacturing, carries no manufacturer dosing device, and sits outside the STEP and SURMOUNT trial evidence — all of which was generated with the branded products. The FDA has issued repeated warnings about compounded GLP-1 products, and with branded supply restored, the legal basis for mass compounding has narrowed. The price gap between a $149 compounded vial and a $349 branded pen is not savings; it is the difference between the two products. Any honest cost analysis has to price them apart — and a patient choosing on price alone should at least know which product class they are choosing. GoodLife Health prescribes branded, FDA-approved medications only, without exception.

Why the GoodLife number is built differently

The GoodLife number is always two transparent parts. Part one is the $299 clinical fee covering everything clinical — quarterly Biomarker Audits, monthly check-ins, secure messaging, titration management, and hormone optimization when your labs call for it. Part two is the medication at the cheapest channel for your dose: your own pharmacy's price or the manufacturer channel when it is lower — Wegovy pens at $349, Zepbound vials at $299 to $449, Foundayo from $149. That makes the honest cash range $448 a month at an oral entry dose to $748 at injectable maintenance. Members whose own plan covers the medication do better still: the pharmacy bills that insurer and you pay the copay your plan sets, so what reaches you is the $299 membership plus that copay.

Just as important is what the number does over time. On dose-escalation platforms, the maintenance dose is the expensive one — the trap is the titration itself. At GoodLife Health, the clinical fee at 15mg is the same $299 it was at 2.5mg.

The verdict: why the $299 membership with unbundled medication wins

Strip away the branding and every platform above is answering one question: what do you sell, the drug or the medicine? The verdict follows from two kinds of logic.

The business logic is unbundling. Any platform that bundles the drug into its price is long the drug: when manufacturer prices fall — and they fell hard this year — the bundler's margin is squeezed and its price is slow to follow. GoodLife Health is structurally short the drug's price: the membership never contained it, so every manufacturer price cut flows straight to the member through cheapest-channel routing, automatically. A bundled $299 was a great price last year; an unbundled $299 clinical layer plus a $149-to-$449 open-market drug is a better one every year the price war continues — and it never reprices you at maintenance, because there is no margin to defend. The fee buys only things whose value does not decay with the drug's price: the labs, the clinician, the protocol.

The clinical logic is longevity. A GLP-1 prescription is measured in months; cardiometabolic health is measured in decades. The longevity outcome is not a number on a scale — it is ApoB, Lp(a), insulin sensitivity, hormone and thyroid balance, inflammation, and muscle mass held in optimal range for twenty years. Weight-vertical platforms, by design, monitor almost none of that; manufacturer channels monitor nothing at all. The $299 buys the instrument that longevity actually requires — a comprehensive Biomarker Audit every 90 days, read by a named clinician who adjusts the protocol against it — plus the endocrine axis every weight program skips, muscle-preservation targets while the weight comes off, and a deprescribing path for the day your labs say the drug has done its job. On every other model in the tables above, that last day is a lost customer. Here it is the product working.

That is the whole argument, in one sentence each: unbundling means the market's falling drug prices work for you, and the flat fee buys the only things that compound — a clinical relationship and a quarterly measurement of whether you are actually getting healthier.

ROI in clinical terms, not just dollars

The same molecules produce the same trial results everywhere — roughly 15% average weight loss on semaglutide 2.4mg (STEP 1) and up to about 21% on tirzepatide (SURMOUNT-1). What differs across platforms is everything around the molecule, which is where the return actually lives. At GoodLife Health the $299 buys the system the drug operates in: four comprehensive Biomarker Audits a year ($1,000 to $2,000 at retail) that catch the thyroid, hormone, ApoB, and insulin problems a weight program never looks for; hormone optimization included when indicated ($150 to $250 a month at a dedicated clinic); a named clinician managing titration against your labs with muscle-preservation targets; and a deprescribing path — because the platform earns nothing on the prescription, tapering when your labs support it is a success, not lost revenue. No other model in the table is structurally able to say that last sentence.

The clinical facts make the gap concrete. Roughly half of heart attacks occur in people with “normal” standard cholesterol — ApoB and Lp(a) exist precisely to see the risk LDL-C misses, and no weight vertical in this comparison measures either. Fasting insulin rises years before glucose looks abnormal, which makes insulin resistance invisible to a glucose-only screen until it has matured into prediabetes. An undertreated thyroid stalls weight protocols outright. And rapid weight loss without protein targets and monitoring costs muscle — the single tissue longevity depends on most. These are not add-ons to weight care; they are the reasons weight care fails when they are ignored. Measuring and managing them every 90 days is what the membership is.

The question that sorts every platform

Ask one question of any GLP-1 provider: "What is my all-in monthly cost at the maintenance dose, including labs?" Platforms built on medication margin cannot answer it cleanly, because the honest answer is their marketing problem. Platforms built on Aligned Medicine can answer it in one line — which is, in the end, the entire difference.

Year one, all-in

Monthly numbers hide the fees that only strike once, so run the first year honestly. At GoodLife Health, year one of the clinical relationship is $3,588 ($598 first charge covering two months, then $299 × 10) — including all four Biomarker Audits, worth $1,000 to $2,000 at retail — plus the medication at the cheapest channel for your protocol: roughly $1,788 a year on a manufacturer-direct oral entry dose, $4,188 on Wegovy pens at $349, up to $5,388 at Zepbound maintenance. With insurance covering the medication, year one lands near $3,888 to $4,188 all-in.

The comparison set at the same 2026 prices: Hims on bundled branded Wegovy runs $3,588 a year — a genuinely comparable number that buys a weight program without comprehensive labs or an endocrine axis; Noom Med's stacked fees plus branded medication commonly exceed $7,800; manufacturer direct runs $1,788 to $5,388 for the drug alone with no clinical layer; concierge and hormone-clinic models run $10,800 to $18,000+, before $299+ intake fees and $450+ lab packages. Money well spent is a claim you check against what each dollar buys: here, every dollar of clinical spend lands on care whose results are measured in your own quarterly labs — and none of it lands on medication margin.

The whole picture is the product

Sum it up from the top. More than 130 million American adults live with diabetes or prediabetes, and only 12% are metabolically healthy — and the market's answer is a shelf of weight-loss verticals selling access to one molecule at war over its price. That war is real and this page prices it honestly: the drug has never been cheaper, and through cheapest-channel routing, GoodLife Health members buy it at whatever the market's floor is this month.

But weight is one axis of a stack. The person carrying it also has an endocrine system, a lipid panel, an insulin curve, an inflammatory state, and muscle to protect — and in the body those are one system, whether or not a platform is built to see it. Every competitor in the tables above treats the axis. The $299/month Cardiometabolic Optimization Membership treats the stack: quarterly Biomarker Audits that measure all of it, a named clinician who reads all of it together, hormone and thyroid optimization when indicated, muscle-preserving weight protocols, and an economic structure — flat fee, zero medication margin, revenue only from retention — that is rewarded only when the whole picture improves for years, not when one number improves for a season. That is what is truly different, and it is exactly what the price buys: not a cheaper way to take a drug, but the only model in the comparison built to make you durably healthier than you were.

FAQ

What is the true monthly cost of GLP-1 telehealth? Clinical fee plus medication plus labs, at current published prices. In August 2026: $149 to $449 for drug-only manufacturer channels, $299 to $399 bundled at Hims, $149 to $249 on Ro's compounded track, $650+ stacked at Noom Med on branded therapy, $900 to $1,500+ at concierge clinics — and $448 to $748 cash at GoodLife Health with comprehensive quarterly labs and full cardiometabolic care included.

Why do advertised prices differ so much from real costs? Because most platforms advertise the membership and exclude the medication, quote starting-dose prices rather than maintenance, and bill labs and intake separately. The all-in number at the maintenance dose is the only comparable figure.

What does GoodLife Health cost all-in with insurance? The membership is $299 a month. Where your own plan covers the branded medication, the pharmacy bills your insurer and you pay whatever copay your plan sets — we take no share of it.

Does the GoodLife Health cost rise at higher doses? Only by the pharmacy's own price difference. The $299 clinical fee is identical at every dose and for every molecule; there is no dose-escalation repricing.

What does the first year at GoodLife Health cost all-in? The clinical relationship is $3,588 for year one ($598 first charge covering two months, then $299 × 10), including all four Biomarker Audits. Medication adds the cheapest channel price for your protocol — roughly $1,788 a year at a manufacturer-direct oral entry dose, up to $5,388 at injectable maintenance — or a copay where insurance covers it, putting year one near $3,888 to $4,188 all-in.

How does that compare with the alternatives over a year? At 2026 prices: Hims on bundled branded Wegovy runs $3,588 a year without comprehensive labs or an endocrine axis. Noom Med's stacked fees plus branded medication commonly exceed $7,800. Manufacturer direct runs $1,788 to $5,388 for the drug alone with no clinical layer. Concierge and hormone-clinic models run $10,800 to $18,000 or more, before intake fees and lab packages.

Hims includes branded Wegovy at $299 — why pay GoodLife Health $299 plus medication? Because the two $299s buy different products. Hims' $299 bundles the drug into a weight-vertical program. GoodLife Health's $299 buys the clinical system around the drug: four comprehensive Biomarker Audits a year (retail value $1,000 to $2,000), hormone and thyroid optimization when indicated, a named clinician, and a deprescribing path — with the medication itself routed to the cheapest channel, at cost. If the goal is taking a drug, the bundle is cheaper. If the goal is fixing the system the drug operates in, the bundle does not contain it.

Why not just buy from NovoCare or LillyDirect directly? For the drug alone, those channels are excellent — and GoodLife Health routes prescriptions through them when they are cheapest for your dose. What they do not include is any of the medicine around the molecule: no comprehensive labs, no contraindication and thyroid screening, no titration judgment, no hormone axis, no one accountable for your trajectory. The membership is the clinical layer; the manufacturer channel is just the shelf.

Is compounded semaglutide just a cheaper version of the same drug? No. Compounded GLP-1s are pharmacy-made copies that have not passed FDA review of their manufacturing, carry no manufacturer dosing device, and sit outside the STEP and SURMOUNT trial evidence, which was generated entirely with branded products. That is why this analysis prices them in a separate table: the gap between a $149 compounded vial and a $349 branded pen is the difference between two products, not a discount on one. GoodLife Health prescribes branded, FDA-approved medications only.

Sources and pricing notes

Platform prices are published self-pay rates as of August 2026: NovoCare and LillyDirect from the manufacturers' pricing pages; Hims, Ro, Noom, Found, Mochi, LifeMD, Sesame, WeightWatchers Clinic, and Calibrate from their published pricing as reported on their sites and in current independent reviews. The GoodLife Health figure is the membership fee only; it takes no margin on medication and does not set medication prices. Where platforms change prices, this page is updated; the structural comparison does not depend on any single number.

Related guides

• What branded GLP-1 medications actually cost
• The GLP-1 dose-escalation trap
• Aligned Medicine: how zero-markup healthcare works
• Pricing at GoodLife Health